BBS

Social Enterprise Summit Gathers Leaders from Civil, Business, Government and Academic Sectors  to“Bounce Forward Together”

Retrieved on: 
Sunday, November 27, 2022
Chinachem, KONG, BBS, Administration, IDSM, Golden Joystick Awards, NEWS, Home Affairs Department, Government of Hong Kong, Belinda, International Symposium on Personal, Indoor and Mobile Radio Communications, Australian Youth Affairs Coalition, Movement, Keynote, Pharmacy, Government, HKSAR, DBS Bank, Interior minister, Birmingham Organising Committee for the 2022 Commonwealth Games, GBS, Speech, GSG, MH, SES, Impact, Convention center, SAR, HK, Management, Limited

HONG KONG SAR - Media OutReach - 24 November 2022 - The 15th Social Enterprise Summit (SES 2022) International Symposium kicks off today at Hong Kong Convention and Exhibition Centre.

Key Points: 
  • HONG KONG SAR - Media OutReach - 24 November 2022 - The 15th Social Enterprise Summit (SES 2022) International Symposium kicks off today at Hong Kong Convention and Exhibition Centre.
  • Mrs Rebecca CHOY YUNG, Chair of Social Enterprise Summit Organising Committee, said: Since its inception, SES has made a significant impact in driving social innovation.
  • I am very proud to see how SES grew from a local conference to a prominent movement and platform over the last 15 years.
  • It has also engaged over 1,200 thought leaders from different sectors as speakers and developed a community of 70,000 participants around the world.

2023 Mazda MX-5: Pricing and Packaging

Retrieved on: 
Thursday, November 17, 2022
Well, Canada, PDE, LED, Glass, Tax, MSRP, Ministry of Education (Malaysia), MX-5, Recaro, Bluetooth, Safety, Defogger, Mazda, Torque, Connect, Bilstein, Bose, Sale, BBS, Sirius XM, CarPlay, RF, Travel, HomeLink Wireless Control System, GS, IPhone, Android Auto, KPC, Radio, USB, GT, Hydraulic machinery, Cable television, Mobile phone, Brembo

RICHMOND HILL, ON, Nov. 17, 2022 /CNW/ - Mazda Canada Inc. today announces updates to the 2023 Mazda MX-5, which continues its long-standing tradition as a pure expression of effortless, joyful driving.

Key Points: 
  • RICHMOND HILL, ON, Nov. 17, 2022 /CNW/ - Mazda Canada Inc. today announces updates to the 2023 Mazda MX-5, which continues its long-standing tradition as a pure expression of effortless, joyful driving.
  • On sale this winter, the 2023 MX-5 will give customers a new exterior paint colour option to choose from in Zircon Sand to help make their MX-5 their own.
  • The MX-5 GS-P and GT are offered in either a manual transmission or a quick-shifting six-speed automatic transmission with steering wheel-mounted paddle shifters.
  • New for 2023, GS-P models and above are available in Zircon Sand exterior paint.

2023 Mazda MX-5 Miata: Pricing and Packaging

Retrieved on: 
Thursday, November 17, 2022
Well, Brembo, LED, Glass, Lane departure warning system, Lip, Miata, Ministry of Education (Malaysia), MX-5, Recaro, Bluetooth, Safety, Defogger, Sport, Torque, Connect, Traffic-sign recognition, Bilstein, Sale, Bose, Sirius XM, BBS, CarPlay, System, HomeLink Wireless Control System, IPhone, Grand tourer, Android Auto, KPC, Radio, USB, Blind spot monitor, Mazda, Club

IRVINE, Calif., Nov. 17, 2022 /PRNewswire/ -- Mazda North America Operations today announces updates to the 2023 Mazda MX-5 Miata, which continues its long-standing tradition as a pure expression of effortless, joyful driving.

Key Points: 
  • IRVINE, Calif., Nov. 17, 2022 /PRNewswire/ -- Mazda North America Operations today announces updates to the 2023 Mazda MX-5 Miata, which continues its long-standing tradition as a pure expression of effortless, joyful driving.
  • On sale this winter, the 2023 MX-5 Miata will give customers a new exterior paint color option to choose from in Zircon Sand to help make their MX-5 their own.
  • This pulls down on that corner, suppressing body roll, and making steering response feel more linear through tight or rough corners.
  • Terracotta Nappa leather seats are an upgradable option to the MX-5 Miata Grand Touring's standard black leather seats.

The Global Automotive Wheel Market is expected to grow by $11.20 bn during 2022-2026, accelerating at a CAGR of 4.57% during the forecast period

Retrieved on: 
Tuesday, November 15, 2022
Trelleborg (company), Industry, FORCE America, Inc., Research, CITIC, Topy Industries, CVS, BBS, Retail

View original content:https://www.prnewswire.com/news-releases/the-global-automotive-wheel-mar...

Key Points: 
  • This study identifies the development of ultra-lightweight automotive wheels for CVs as one of the prime reasons driving the automotive wheel market growth during the next few years.
  • Also, growing online purchases of automotive products and technological advancements, and product developments in design and material will lead to sizable demand in the market.
  • Also, the automotive wheel market analysis report includes information on upcoming trends and challenges that will influence market growth.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

PCPD Organised a Webinar on “Protection of Personal Data Privacy for Property Management Sector”

Retrieved on: 
Friday, November 11, 2022
Privacy Commissioner, Data management, BBS, Guidance, Privacy, Complaint, Personal data, SBS, Personal Data Privacy and Security Act of 2009, Property management

The PCPD organised a webinar on Protection of Personal Data Privacy for Property Management Sector on 27 July 2022.

Key Points: 
  • The PCPD organised a webinar on Protection of Personal Data Privacy for Property Management Sector on 27 July 2022.
  • The event attracted more than 700 participants from the property management sector and the general public.
  • At the webinar, which was supported by the Property Management Services Authority, the Privacy Commissioner for Personal Data (Privacy Commissioner), Ms Ada CHUNG Lai-ling introduced to the participants the key findings of the recent investigation report on the improper handling of the personal data of residents and visitors by property management companies, while Ms Amy CHAN Mei-yee, Chief Personal Data Officer (Complaints) of PCPD, elaborated on the new edition of the Guidance for the Property Management Sector issued by the PCPD last month.
  • The Privacy Commissioner Ms Ada CHUNG Lai-ling (top left), Immediate Past President of the Hong Kong Association of Property Management Companies and Chief Executive Officer of Savills Services Group Dr Johnnie CHAN Chi-kau, SBS, BBS, JP (top right), and Chief Personal Data Officer (Complaints) of PCPD Ms Amy CHAN Mei-yee (bottom), spoke at a webinar on Protection of Personal Data Privacy for Property Management Sector.

PCPD Reruns the Public Webinar on “Protection of Personal Data Privacy for Property Management Sector”

Retrieved on: 
Friday, November 11, 2022
Privacy Commissioner, Data management, BBS, Guidance, Privacy, Complaint, Personal data, SBS, Personal Data Privacy and Security Act of 2009, Property management

The PCPD re-organised the public webinar on Protection of Personal Data Privacy for Property Management Sector on 20 September owing to the overwhelming response to the first webinar held in July this year.

Key Points: 
  • The PCPD re-organised the public webinar on Protection of Personal Data Privacy for Property Management Sector on 20 September owing to the overwhelming response to the first webinar held in July this year.
  • The webinar attracted more than 650 participants from the property management sector and the general public.
  • The Privacy Commissioner for Personal Data (Privacy Commissioner), Ms Ada CHUNG Lai-ling introduced to the participants the key findings of the recent investigation report on the improper handling of the personal data of residents and visitors by four property management companies, while Ms Amy CHAN Mei-yee, Head of Complaints of PCPD, elaborated on the new edition of the Guidance for the Property Management Sector issued by the PCPD recently.
  • The Privacy Commissioner Ms Ada CHUNG Lai-ling (left), Immediate Past President of the Hong Kong Association of Property Management Companies and Chief Executive Officer of Savills Services Group Dr Johnnie CHAN Chi-kau, SBS, BBS, JP (middle), and Head of Complaints of PCPD, Ms Amy CHAN Mei-yee (right), spoke at the webinar on Protection of Personal Data Privacy for Property Management Sector.

Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Clinical Trial of IMCIVREE® (setmelanotide) in Bardet-Biedl Syndrome in The Lancet Diabetes and Endocrinology

Retrieved on: 
Tuesday, November 8, 2022
People, GLOBE, Polyphagia, BBS, Government budget balance, Adult, MC4R, Visual impairment, SD, Weight, University of Alberta, Nasdaq, Hypogonadism, Bardet–Biedl syndrome, Department, BMI, Faculty, Very early onset inflammatory bowel disease, Obesity, Hunger, Patient, Safety, Weight loss, University of Melbourne Faculty of Medicine, Dentistry and Health Sciences, University, Life, The Lancet, Polydactyly, Medicine, Pharmaceutical industry, Endocrinology, EU

BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced that previously disclosed results from a Phase 3 clinical trial that evaluated IMCIVREE® (setmelanotide), an MC4R agonist, in patients with Bardet-Biedl syndrome (BBS) have been published in the peer-reviewed journal The Lancet Diabetes and Endocrinology. The trial met its primary endpoint and all key secondary endpoints, with statistically significant reductions in weight and hunger at 52 weeks on therapy.

Key Points: 
  • People living with BBS may experience insatiable hunger, also known as hyperphagia, and severe obesity beginning early in life.
  • Rhythms multicenter Phase 3 trial (NCT03746522) enrolled patients 6 years old with obesity and BBS or Alstrm syndrome (N=38).
  • The primary endpoint was the proportion of patients 12 years old in the full analysis set achieving 10% weight reduction after 52 weeks.
  • As previously disclosed, treatment with setmelanotide resulted in significant weight and hunger reductions after one year of treatment among patients with BBS.

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

Retrieved on: 
Monday, November 7, 2022
Pigment, Plasma, VUS, Growth, Private Securities Litigation Reform Act, Excipient, Proopiomelanocortin, Benzyl alcohol, Blood pressure, PCSK1, Bardet–Biedl syndrome, Nasdaq, Professional Football Compensation Committee, Toxicity, Population, Weight loss, Risk, Time, Financial compensation, Pregnancy, Skin, Obesity, Depression, United, COVID-19, Alström syndrome, BBS, Product, DNA, Genetic testing, Milk, Hunger, GLOBE, Priapism, RSU, FDA, Patient, Medicines and Healthcare products Regulatory Agency, Data analysis, Heart rate, Fertility, Child, Safety, Adult, MC4R, Food, Diagnosis, Cyprus Securities and Exchange Commission, Metabolic acidosis, LEPR, EC, Allergy, Employment, MHRA, Polyphagia, Pharmaceutical industry, Dietary supplement, Medicine, Birth control, Setmelanotide, European, POMC

About Rhythm PharmaceuticalsRhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases. Rhythm’s precision medicine, setmelanotide, is approved by the U.S. Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity due to pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency confirmed by genetic testing, or patients with a clinical diagnosis of Bardet-Biedl syndrome (BBS). The European Commission (EC) has authorized setmelanotide for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 6 years of age and above.The UK’s Medicines & Healthcare Products Regulatory Agency (MHRA) authorized setmelanotide for the treatment of obesity and the control of hunger associated with genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 6 years of age and above. Additionally, Rhythm is advancing a broad clinical development program for setmelanotide in other rare genetic diseases of obesity and is leveraging the Rhythm Engine and the largest known obesity DNA database -- now with approximately 45,000 sequencing samples -- to improve the understanding, diagnosis and care of people living with severe obesity due to certain genetic deficiencies. Rhythm’s headquarters is in Boston, MA.

Key Points: 
  • These inducement stock options and inducement RSUs are subject to the terms of the Rhythm Pharmaceuticals, Inc. 2022 Employment Inducement Plan (the "Inducement Plan").
  • The Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to the employees entering into employment with Rhythm pursuant to Nasdaq Listing Rule 5635(c)(4).
  • The Inducement Plan was adopted by Rhythms board of directors on February 9, 2022.
  • Rhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases.

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

Retrieved on: 
Thursday, October 6, 2022
Skin, Polyphagia, Diarrhea, Abdominal pain, Depression, Financial compensation, BBS, Obesity, Pigment, Vomiting, Proopiomelanocortin, EC, Sexual arousal, Suicidal ideation, DNA, Fetus, European Commission, Regulation of tobacco by the U.S. Food and Drug Administration, Senior, Private Securities Litigation Reform Act, Incidence, RSU, Genetic testing, Hunger, GLOBE, FDA, Bardet–Biedl syndrome, Nausea, MHRA, Diagnosis, Employment, Risk, Professional Football Compensation Committee, Headache, Alström syndrome, Data analysis, Cyprus Securities and Exchange Commission, Medicines and Healthcare products Regulatory Agency, LEPR, Patient, PCSK1, Nasdaq, Food, MC4R, Setmelanotide, VUS, Adult, Safety, Pregnancy, COVID-19, Pharmaceutical industry, Birth control, POMC

These inducement stock options and inducement RSUs are subject to the terms of the Rhythm Pharmaceuticals, Inc. 2022 Employment Inducement Plan (the "Inducement Plan").

Key Points: 
  • These inducement stock options and inducement RSUs are subject to the terms of the Rhythm Pharmaceuticals, Inc. 2022 Employment Inducement Plan (the "Inducement Plan").
  • The Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to the employees entering into employment with Rhythm pursuant to Nasdaq Listing Rule 5635(c)(4).
  • The Inducement Plan was adopted by Rhythms board of directors on February 9, 2022.
  • To report SUSPECTED ADVERSE REACTIONS, contact Rhythm Pharmaceuticals at 833-789-6337 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

Rhythm Pharmaceuticals, Inc. Announces Closing of $124.8 Million Public Offering

Retrieved on: 
Monday, September 19, 2022
EMANATE, Suite, MC4R, Sale, LLC, S-3, PCSK1, Company, Obesity, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Patient, BBS, Montgomery Street, POMC, Nasdaq, Telephone, Polyphagia, Form, LEPR, Security (finance), Degenerative disease, Attention, GLOBE, SEC, Rhythm, Wells Fargo, Pharmaceutical industry, Incorporated, Stifel

The aggregate gross proceeds to Rhythm from the offering were $124.8 million, before underwriting discounts and commissions, and offering expenses.

Key Points: 
  • The aggregate gross proceeds to Rhythm from the offering were $124.8 million, before underwriting discounts and commissions, and offering expenses.
  • In addition, Rhythm has granted the underwriters a 30-day option to purchase up to an additional 720,000 shares of its common stock at the public offering price, less the underwriting discount and commission.
  • All of the shares in the offering were offered by Rhythm.
  • Cowen, Stifel and Wells Fargo Securities are acting as joint book-running managers for the offering.